Clinical Trial Update: Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations [Phase 2]

View source ↗

Summary

Completion of a Phase 2 trial evaluating the combination of temsirolimus and irinotecan in treatment-resistant metastatic colorectal cancer with KRAS mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Camptosar (irinotecan)
• Torisel (Temsirolimus)

Snippet

Sponsor: Vejle Hospital | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: COMPLETED